<i>Eubacterium limosum</i> modulates gut microbiota and produces anti-inflammatory metabolites to alleviate DSS-induced colitis.

ABSTRACT:

Introduction

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the intestine, for which no cure currently exists. The gut microbiota play a critical role in ameliorating IBD, and Eubacterium limosum has emerged as a potential probiotic with anti-inflammatory properties. However, the specific anti-inflammatory effects of E. limosum and the underlying mechanisms remain largely unexplored.

Methods

The E. limosum strain El1405 was utilized to evaluate its effects on dextran sodium sulfate (DSS)-induced murine colitis. The structural changes in intestinal microbiota were assessed using 16S rRNA gene sequencing. Inflammatory cytokines in the colon and serum were measured via enzyme-linked immunosorbent assay, while metabolomics was employ

SUBMITTER: Lu Y 

PROVIDER: S-EPMC12747957 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature